Physician profile
Ron J Bahar
NPI 1750479002
$3,143.34
in general payments reported to CMS, 2019-2025
22 companies · $979 in 2025
The $979 reported for 2025 was more than what 82% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $671 · 2021: $300 · 2022: $306 · 2023: $157 · 2024: $730 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.74 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $848.26 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $590.49 | 2022-2025 | Dupixent |
| Genzyme Corporation | $574.74 | 2022-2025 | |
| Janssen Biotech, INC. | $204.83 | 2019-2025 | Tremfya, Stelara, Simponi |
| Novo Nordisk INC | $146.36 | 2025 | Wegovy, Saxenda |
| Biohaven Pharmaceuticals, INC. | $124.09 | 2021 | |
| Novartis Pharmaceuticals Corporation | $121.90 | 2019 | |
| Romark Laboratories, Lc | $101.10 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.16 | 2024 | Eohilia |
| Capsovision, INC. | $61.90 | 2025 | Capsocam Plus |
| Qol Medical, LLC | $43.42 | 2019-2025 | Sucraid |
| Pfizer INC. | $38.63 | 2019 | |
| Phadia US INC. | $35.21 | 2023-2024 | Immunocap |
| Concordia Pharmaceuticals INC. | $33.90 | 2019 | |
| Sandoz INC. | $28.76 | 2024 | Hyrimoz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $27.30 | 2021 | |
| Ironwood Pharmaceuticals, INC | $23.15 | 2024 | |
| Nestle Healthcare Nutrition INC. | $19.72 | 2022 | |
| Albireo Pharma, INC. | $19.38 | 2022 | |
| Mirum Pharmaceuticals, INC. | $18.73 | 2022 | |
| Janssen Scientific Affairs, LLC | $16.48 | 2019 | |
| Travere Therapeutics, INC. | $0.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ron Bahar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.